[1]Lettersindrugdesignanddiscovery,2016,vol.13,p.800-808
109925-42-0
109925-13-5
109925-28-2
158712-22-2
321848-47-9
446276-23-9
345637-71-0 | (5-Methyl-3-trifluoromethyl-pyrazol-1-yl)-acetic acid | AA007ETB | MFCD00297315
33422-35-4 | Ethyl 2-(3-oxo-2-piperazinyl)acetate | AA007FB9 | MFCD00052897
333985-79-8 | 1-(Dimethylcarbamoyl)piperidine-4-carboxylic acid | AA007FRV | MFCD03830325
154235-83-3 | Piperidin-1-yl(quinoxalin-6-yl)methanone | AA007G8K | MFCD00943201
3230-94-2 | L-Ornithine l-aspartate salt | AA007GQE | MFCD00058084
34825-70-2 | 1-Amino-5-hexene | AA007H68 | MFCD02258452
153747-97-8 | 2-(4-BOC-piperazino)-5-bromopyridine | AA007HMD | MFCD07369772
153506-14-0 | Acetamide,N-(5-chloro-2-hydroxy-4-methylphenyl)- | AA007I5N | MFCD00020141
317318-70-0 | 2-{2-methyl-4-[({4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}methyl)sulfanyl]phenoxy}acetic acid | AA007ILV | MFCD09033000
1027833-17-5 | 1-Bromo-2-chloro-5-fluoro-4-nitrobenzene | AA007J3Y | MFCD11110551